About Myriad Genetics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://myriad.com/
Frequently Asked Questions
What is the 52-week range for MYGN?
The 52-week high is $8.59 and the 52-week low is $2.74.
What is the P/E ratio for MYGN?
The P/E ratio data is currently unavailable.
What is the dividend yield for MYGN?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -32.59%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -13.96%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.56.
Analyst Recommendation Trends
Wall Street analyst consensus for MYGN over the last few months:
Latest MYGN News
Why Is Myriad Genetics (MYGN) Stock Soaring Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 5% in the afternoon session after Craig-Hallum analyst John Wilkin raised the firm's price target on the stock to $8, StreetInsider reported.
Craig-Hallum Maintains Buy on Myriad Genetics, Raises Price Target to $8
Craig-Hallum analyst John Wilkin maintains Myriad Genetics (NASDAQ:MYGN) with a Buy and raises the price target from $4 to $8.
1 Volatile Stock on Our Buy List and 2 We Question
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared.
3 Reasons MYGN is Risky and 1 Stock to Buy Instead
Over the past six months, Myriad Genetics’s stock price fell to $4.01. Shareholders have lost 13% of their capital, which is disappointing considering the S&P 500 has climbed by 18.4%. This was partly due to its softer quarterly results and might have investors contemplating their next move.
Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges
Quest Diagnostics (NYSE:DGX) CEO and President Jim Davis said the diagnostic testing company is exceeding the growth framework it outlined at its prior investor day, driven largely by organic growth, consumer-health demand and partnerships rather than a heavier-than-expected pace of acquisitions. D
Myriad Genetics (MYGN) Stock Fair Value Moves Lower After Analyst Cuts And Guidance Reset
Myriad Genetics is back in focus after a sharp reset in analyst price targets, with the modelled fair value estimate moving from about US$6.25 to roughly US$3.37, a cut of close to 46%. The shift lines up with more cautious Street commentary that concentrates on execution risk, profitability, and the impact of reduced FY26 guidance on how the stock is valued. As you read on, you will see how to interpret these updates and how to follow the evolving narrative around Myriad Genetics. Stay...
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares moved upwards by 30.0% to $2.08 during Thursday's after-market session. The company's market cap stands at $3.2 million. cbdMD (AMEX:YCBD) stock increased by
1 Unpopular Stock That Deserves Some Love and 2 We Turn Down
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been promoted to Executive Vice President - Commercial, effective September 16, 2026. Vishal has served as the SVP of Product at Myriad for the past year. He has deep understanding of molecular diagnostics and oncology as well as extensive business and commercial leadership experience from his prior roles
Myriad Genetics Affirms FY2026 Sales Guidance of $770.000M-$790.000M vs $776.790M Est
Myriad Genetics (NASDAQ:MYGN) affirms FY2026 sales outlook from $770.000 million-$790.000 million to $770.000 million-$790.000 million vs $776.790 million estimate.
2 Unprofitable Stocks to Research Further and 1 We Find Risky
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
Why RH Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
RH shares jumped 8.2% premarket after EPS beat estimates despite a revenue miss; Oracle and others gained, while OPTT and ZUMZ fell.
UBS Maintains Neutral on Myriad Genetics, Lowers Price Target to $3.6
UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and lowers the price target from $6 to $3.6.
Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN)
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers.
Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound?
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?
Harmony Biosciences (HRMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-21 | Wheeler Benjamin Richard | -2,555 | $4.01 | $10,246 |
| 2026-09-16 | Sikri Vishal | +257,731 | - | - |
| 2026-09-03 | Fox Jennifer Lynne | -4,398 | $3.23 | $14,206 |
| 2026-08-16 | Wheeler Benjamin Richard | -8,761 | $3.03 | $26,546 |
| 2026-06-11 | Donnelly Brian J | +5,000 | $3.936 | $19,680 |
| 2026-06-11 | Raha Samraat S. | +3,542 | $3.936 | $13,941 |
| 2026-06-08 | Kumar Rashmi | -15,000 | $4.4562 | $66,843 |
| 2026-06-04 | Davis Mark Steven | +59,701 | - | - |
| 2026-06-04 | Kumar Rashmi | +59,701 | - | - |
| 2026-06-04 | Newcomer Lee Nisley | +59,701 | - | - |
| 2026-06-04 | Skovronsky Daniel | +59,701 | - | - |
| 2026-06-04 | Reitan Colleen F | +59,701 | - | - |
| 2026-06-04 | Phanstiel S. Louise | +59,701 | - | - |
| 2026-06-04 | Dreismann Heinrich | +59,701 | - | - |
| 2026-06-04 | Bisaro Paul | +59,701 | - | - |
| 2026-06-01 | Jampa Raj | +251,889 | - | - |
| 2026-05-14 | Bisaro Paul | +7,500 | $3.685 | $27,638 |
| 2026-05-01 | Donnelly Brian J | -55,975 | $4.8 | $268,680 |
| 2026-04-14 | Muzzey Dale | -946 | $4.91 | $4,645 |
| 2026-04-14 | Verratti Mark | -1,069 | $4.91 | $5,249 |
| 2026-03-22 | Wheeler Benjamin Richard | -549 | $4.58 | $2,514 |
| 2026-03-22 | Muzzey Dale | -2,019 | $4.58 | $9,247 |
| 2026-03-22 | Verratti Mark | -2,055 | $4.58 | $9,412 |
| 2026-03-15 | Wheeler Benjamin Richard | -2,192 | $4.66 | $10,215 |
| 2026-03-15 | Wheeler Benjamin Richard | -877 | $4.66 | $4,087 |
| 2026-03-15 | Muzzey Dale | -11,949 | $4.66 | $55,682 |
| 2026-03-15 | Muzzey Dale | -4,783 | $4.66 | $22,289 |
| 2026-03-15 | Haas Kevin Richard | -8,382 | $4.66 | $39,060 |
| 2026-03-15 | Haas Kevin Richard | -3,355 | $4.66 | $15,634 |
| 2026-03-15 | Verratti Mark | -9,096 | $4.66 | $42,387 |
| 2026-03-15 | Verratti Mark | -5,611 | $4.66 | $26,147 |
| 2026-03-14 | Wheeler Benjamin Richard | -1,097 | $4.66 | $5,112 |
| 2026-03-14 | Muzzey Dale | -8,288 | $4.66 | $38,622 |
| 2026-03-14 | Haas Kevin Richard | -4,161 | $4.66 | $19,390 |
| 2026-03-14 | Raha Samraat S. | -10,816 | $4.66 | $50,403 |
| 2026-03-14 | Verratti Mark | -5,418 | $4.66 | $25,248 |
| 2026-03-14 | Solaiman Shereen | -5,784 | $4.66 | $26,953 |
| 2026-03-13 | Wheeler Benjamin Richard | -586 | $4.66 | $2,731 |
| 2026-03-13 | Muzzey Dale | -12,779 | $4.66 | $59,550 |
| 2026-03-13 | Fox Jennifer Lynne | -5,995 | $4.66 | $27,937 |
| 2026-03-13 | Haas Kevin Richard | -6,412 | $4.66 | $29,880 |
| 2026-03-13 | Raha Samraat S. | -36,304 | $4.66 | $169,177 |
| 2026-03-13 | Verratti Mark | -9,164 | $4.66 | $42,704 |
| 2026-03-13 | Solaiman Shereen | -8,899 | $4.66 | $41,469 |
| 2026-03-12 | Wheeler Benjamin Richard | +206,186 | - | - |
| 2026-03-12 | Donnelly Brian J | +226,804 | - | - |
| 2026-03-12 | Muzzey Dale | +173,196 | - | - |
| 2026-03-12 | Fox Jennifer Lynne | +195,876 | - | - |
| 2026-03-12 | Raha Samraat S. | +618,557 | - | - |
| 2026-03-12 | Verratti Mark | +247,423 | - | - |
| 2026-03-12 | Solaiman Shereen | +173,196 | - | - |
| 2026-03-09 | Raha Samraat S. | +40,000 | $4.9961 | $199,844 |
| 2026-03-01 | Solaiman Shereen | -1,675 | $4.61 | $7,722 |
| 2026-02-27 | Phanstiel S. Louise | +48,000 | $4.661 | $223,728 |
| 2026-02-26 | Phanstiel S. Louise | +50,407 | $4.803 | $242,105 |
| 2026-02-25 | Phanstiel S. Louise | +6,100 | $4.736 | $28,890 |
| 2026-02-02 | Wheeler Benjamin Richard | +4,994 | - | - |
| 2026-02-02 | Muzzey Dale | +23,697 | - | - |
| 2026-02-02 | Haas Kevin Richard | +23,697 | - | - |
| 2026-02-02 | Verratti Mark | +32,810 | - | - |
| 2026-01-01 | Muzzey Dale | -418 | $6.15 | $2,571 |
| 2025-12-25 | Wheeler Benjamin Richard | -21 | $6.55 | $138 |
| 2025-12-11 | Raha Samraat S. | -29,634 | $7.3 | $216,328 |